The Lactobacillus brevis 47 f Strain Protects the Murine Intestine from Enteropathy Induced by 5-Fluorouracil

Abstract

We report that the results of our study indicate that Lactobacillus brevis 47 f strain isolated from the faeces of a healthy individual prevents the manifestations of experimental mucositis induced by treatment of Balb/c mice with the anticancer drug 5-fluorouracil (5 FU; 100 mg/kg i.p. × 3 days). The presence of damage to the intestine and the colon was determined by a morphometric analysis of specimens including the height of villi, the amount of goblet cells and infiltrating mononuclear cells, and the expression of the proliferative Ki-67 antigen. Changes in the lipid peroxidation in the blood and the intestine were determined by severalfold increase of the concentration of malonic dialdehyde. Oral administration of L. brevis 47 f strain prior to 5 FU decreased the drug-induced morphological and biochemical changes to their respective physiological levels; the ability of intestinal epitheliocytes to express Ki-67 was partially restored. These effects of L. brevis 47 f strain were more pronounced or similar to those of the reference compound Rebamipid, a quinoline derivative known to protect the gut from drug-induced toxicity. Thus, the new lactobacilli strain attenuates the severity of 5 FU-induced enteropathy.

Biomarkers and Utility of the Antioxidant Potential of Probiotic Lactobacilli and Bifidobacteria as Representatives of the Human Gut Microbiota

“…L. reuteri DSM 17938 reduced pathological parameters such as the expression of TNF-α and IL-1β, MDA, GSSG, and the GSSG/GSH ratio, and significantly increased SOD activity and GSH levels in mice [70]. The introduction of L. brevis 47f strain to BALB/c mice subjected to 5-fluorouracil (5-FU)-induced mucositis protected enterocytes and decreased MDA blood plasma levels and MDA levels in the intestinal tissues (2-3 times lower than in the positive control group) [71]. The positive AO impact of L. fermentum U-21 strain on paraquat-treated C57/BL6 mice was observed in the study of Marsova et al [72].…”

“…The third step involves the assessment of the antioxidant properties of selected strains of probiotic bacteria in vitro, using cell lines and model organisms. This approach proved effective for the selection of strains such as L. brevis 47f and L. fermentum U-21, which possess outstanding antioxidant properties [61,71,72,[206][207][208][209].…”

Common Inflammatory Mechanisms in COVID-19 and Parkinson’s Diseases: The Role of Microbiome, Pharmabiotics and Postbiotics in Their Prevention

“…Biologically active compounds obtained from the biomass and culture medium of the L. fermentum U-21 strain also have antioxidant activity against superoxide anion and can be used in pharmacology and medicine in the treatment of neurodegenerative diseases induced by oxidative stress, as well as in cosmetology with an increase in antioxidant status of skin. 59,289,290,[333][334][335]…”

The effects of Levilactobacillus brevis on the physiological parameters and gut microbiota composition of rats subjected to desynchronosis

“…The strain L. brevis 47f was grown as previously described [ 26 ] under anaerobic conditions (10% CO2 atmosphere, Anaerobic System Mark II, HiMedia, Mumbai, India) at + 37 °C in MRS medium (HiMedia). To obtain the final product for biological testing, the bacterial culture was cultivated in a fermenter under anaerobic conditions for 18–20 h until it reached the stationary phase (10 9 CFU/mL).…”

“…The cell-free culture supernatant of the strain proved effective in countering oxidative stress triggered by superoxide anion and hydrogen peroxide [ 25 ]. L. brevis 47f also stimulated local anti-inflammatory activity and increased total antioxidant levels in the blood and intestines of BALB/c mice experiencing 5-fluorouracil-induced mucositis [ 26 ].…”